Clinical Research Article | Published:

Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22–27 weeks’ gestation

Pediatric Research (2018) | Download Citation




Early identification of infants at risk for complications from patent ductus arteriosus (PDA) may improve treatment outcomes. The aim of this study was to identify biochemical markers associated with persistence of PDA, and with failure of pharmacological treatment for PDA, in extremely preterm infants.


Infants born at 22–27 weeks’ gestation were included in this prospective study. Blood samples were collected on the second day of life. Fourteen biochemical markers associated with factors that may affect PDA closure were analyzed and related to persistent PDA and to the response of pharmacological treatment with ibuprofen.


High levels of B-type natriuretic peptide, interleukin-6, -8, -10, and -12, growth differentiation factor 15 and monocyte chemotactic protein 1 were associated with persistent PDA, as were low levels of platelet-derived growth factor. High levels of erythropoietin were associated with both persistent PDA and failure to close PDA within 24 h of the last dose of ibuprofen.


High levels of inflammatory markers were associated with the persistence of PDA. High levels of erythropoietin were associated with both the persistence of PDA and failure to respond to pharmacological treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Benitz, W. E. Patent ductus arteriosus in preterm infants. Pediatrics 137, 1–6 (2016).

  2. 2.

    Clyman, R. I., Couto, J. & Murphy, G. M. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol. 36, 123–129 (2012).

  3. 3.

    Gudmundsdottir, A., Johansson, S. & Håkansson, S. et al. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. Neonatology 107, 87–92 (2015).

  4. 4.

    Thankavel, P. P., Rosenfeld, C. R., Christie, L. & Ramaciotti, C. Early echocardiographic prediction of ductal closure in neonates < 30 weeks gestation. J. Perinatol. 33, 45–51 (2012).

  5. 5.

    Zonnenberg, I. & de Waal, K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 101, 247–251 (2012).

  6. 6.

    Evans, N. Preterm patent ductus arteriosus: a continuing conundrum for the neonatologist?. Semin Fetal Neonatal Med 20, 272–277 (2015).

  7. 7.

    El-Khuffash, A., Davis, P. G., Walsh, K. & Molloy, E. J. Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants. J. Perinatol. 28, 482–486 (2008).

  8. 8.

    Mine, K., Ohashi, A., Tsuji, S., Nakashima, J. I., Hirabayashi, M. & Kaneko, K. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Acta Paediatr. 102, 347–352 (2013).

  9. 9.

    Heuchan A.M. & Clyman R.I. Managing the patent ductus arteriosus: current treatment options. Arch. Dis. Child Fetal Neonatal Ed. 99, F431–F436 (2014).

  10. 10.

    Assarsson, E. & Lundberg, M. & Holmquist, G. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PloS ONE 9, e95192 (2014).

  11. 11.

    Olsson, K.W., Jonzon, A. & Sindelar, R. A high ductal flow velocity is associated with successful pharmacological closure of patent ductus arteriosus in infants 22–27 weeks gestational age. Crit. Care Res Pract. 2012, 1–6 (2012).

  12. 12.

    Van Overmeire, B., Van de Broek, H., Van Laer, P., Weyler, J. & Vanhaesebrouck, P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J. Pediatr. 138, 205–211 (2001).

  13. 13.

    Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289–300 (1995).

  14. 14.

    El-Khuffash, A., Barry, D., Walsh, K., Davis, P. G. & Molloy, E. J. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch. Dis. Child Fetal Neonatal Ed. 93, F407–F412 (2008).

  15. 15.

    Lee, J. H., Shin, J. H., Park, K. H., Rhie, Y. J., Park, M. S. & Choi, B. M. Can early b-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants? Neonatology 103, 118–122 (2013).

  16. 16.

    Sorokin, Y., Romero, R. & Mele, L. et al. Umbilical cord serum interleukin-6, C-reactive protein, and myeloperoxidase concentrations at birth and association with neonatal morbidities and long-term neurodevelopmental outcomes. Am. J. Perinatol. 31, 717–726 (2013).

  17. 17.

    D’Angio C.T., Ambalavanan N., Carlo W.A., et al. Blood cytokine profiles associated with distinct patterns of bronchopulmonary dysplasia among extremely low birth weight infants. J Pediatr. 174, 45-51 (2016).

  18. 18.

    Paananen R., Husa A.-K., Vuolteenaho R., Herva R., Kaukola T., Hallman M. Blood cytokines during the perinatal period in very preterm infants: J Pediatr. 154, 39–43.e3 (2009).

  19. 19.

    Lusyati, S., Hulzebos, C. V., Zandvoort, J. & Sauer, P. J. J. Levels of 25 cytokines in the first seven days of life in newborn infants. BMC Res Notes 6, 547 (2013).

  20. 20.

    Bose, C. L., Laughon, M. M. & Allred, E. N. et al. Systemic inflammation associated with mechanical ventilation among extremely preterm infants. Cytokine 61, 315–322 (2013).

  21. 21.

    Lohani, O., Colvin, K. L. & Yeager, M. E. Biomarkers for pediatric pulmonary arterial hypertension: challenges and recommendations. Paediatr. Respir. Rev. 16, 225–231 (2015).

  22. 22.

    Colvin, K. L., Dufva, M. J., Delaney, R. P., Ivy, D. D., Stenmark, K. R. & Yeager, M. E. Biomarkers for pediatric pulmonary arterial hypertension—a call to collaborate. Front Pediatr. 2, 7 (2014).

  23. 23.

    Duncan, M., Wagner, B. D. & Murray, K. et al. Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediat. Inflamm. 2012, 1–7 (2012).

  24. 24.

    Bin-Nun, A., Mimouni, F. B., Fink, D., Sela, H. & Hammerman, C. Elevated nucleated red blood cells at birth predict hemodynamically significant patent ductus arteriosus. J. Pediatr. 177, 10–12 (2016).

  25. 25.

    Krishnan, R., Shankaran, S., Krishnan, M., Kauffman, R. E., Kumar, P. & Lucena, J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. Biol. Neonate 70, 135–140 (1996).

  26. 26.

    Holm, M., & Skranes, J. & Dammann, O. & Fichorova R.N. & Allred E.N. & Leviton A. Systemic endogenous erythropoietin and associated disorders in extremely preterm newborns. Arch Dis Child Fetal Neonatal Ed 101, F458–F463 (2016).

  27. 27.

    Polglase, G. R., Barton, S. K. & Melville, J. M. et al. Prophylactic erythropoietin exacerbates ventilation-induced lung inflammation and injury in preterm lambs. J. Physiol. 592, 1993–2002 (2014).

  28. 28.

    Smith, A., Maguire, M., Livingstone, V. & Dempsey, E. M. Peak systolic to end diastolic flow velocity ratio is associated with ductal patency in infants below 32 weeks of gestation. Arch. Dis. Child Fetal Neonatal Ed. 100, F132–F136 (2015).

  29. 29.

    Occhipinti, F., De Carolis, M. P. & De Rosa, G. et al. Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus. J. Matern Fetal Neonatal Med 27, 1800–1804 (2014).

  30. 30.

    Grass, B., Baumann, P. & Arlettaz, R. et al. Cardiovascular biomarkers pro-atrial natriuretic peptide and pro-endothelin-1 to monitor ductus arteriosus evolution in very preterm infants. Early Hum. Dev. 90, 293–298 (2014).

  31. 31.

    Letzner, J., Berger, F. & Schwabe, S. et al. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus. Neonatology 101, 116–124 (2012).

  32. 32.

    Hong, Z., Cabrera, J. A., Mahapatra, S., Kutty, S., Weir, E. K. & Archer, S. L. Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus. J. Mol. Med 92, 995–1007 (2014).

  33. 33.

    Waleh, N., Seidner, S. & McCurnin, D. et al. Anatomic closure of the premature patent ductus arteriosus: the role of CD14 + /CD163 + mononuclear cells and vegf in neointimal mound formation. Pediatr. Res 70, 332–338 (2011).

  34. 34.

    Clyman, R. I., Seidner, S. R. & Kajino, H. et al. VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R199–206 (2002).

  35. 35.

    Sood, B. G., Delaney-Black, V., Glibetic, M., Aranda, J. V., Chen, X. & Shankaran, S. PGE2/TXB2 imbalance in neonatal hypoxemic respiratory failure. Acta Paediatr. 96, 669–673 (2007).

  36. 36.

    Chen, J.-X., O’Mara, P. W. & Poole, S. D. et al. Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus. Pediatr. Res 72, 122–128 (2012).

  37. 37.

    Wells Logan, J., Allred, E. N., Fichorova, R. N., Engelke, S., Dammann, O. & Leviton, A. Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns. Cytokine 69, 22–28 (2014).

Download references


The authors would like to thank Viktoria Nelin for the suggestions regarding the English language, and the nurses at the Neonatal Intensive Care Unit, Uppsala University Children’s Hospital, Uppsala, and especially the research nurse Cecilia Ewald for her assistance in the collection of blood samples. This study was supported by grants from the Royal Society of Arts and Sciences of Uppsala; Födelsefonden/Perinatalmedicinska Forskningsfonden, Uppsala; the Samariten Foundation for Paediatric Research, Stockholm; Crown Princess Lovisa’s Foundation for Children’s Health Care, Stockholm; the Center for Clinical Research Dalarna; and the Uppsala-Örebro Regional Research Council.

Author information


  1. Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden

    • Karl Wilhelm Olsson
    • , Anders Jonzon
    •  & Richard Sindelar
  2. Department of Medical Sciences, Uppsala University, Uppsala, Sweden

    • Anders Larsson


  1. Search for Karl Wilhelm Olsson in:

  2. Search for Anders Larsson in:

  3. Search for Anders Jonzon in:

  4. Search for Richard Sindelar in:


K.W.O.: conceptualized and designed the study, supervised data collection, designed the custom data handling software, drafted the initial manuscript, and approved the final manuscript as submitted. A.L.: conceptualized and designed the study, carried out analyses of endothelin-1 and thromboxane B2, reviewed and revised the manuscript, and approved the final manuscript as submitted. A.J.: conceptualized and designed the study, carried out the echocardiographic examinations, supervised data collection, reviewed and revised the manuscript, and approved the final manuscript as submitted. R.S.: conceptualized and designed the study, coordinated and supervised data collection, reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Karl Wilhelm Olsson.

About this article

Publication history